Which condition is important to monitor due to potential hepatotoxicity from nevirapine (Viramune)?

Monitoring for hepatotoxicity is critical when a patient is receiving nevirapine (Viramune) due to the drug's potential to cause liver damage. Nevirapine is an antiretroviral medication used in the treatment of HIV, and hepatotoxicity can occur as a serious adverse effect, particularly during the first few months of treatment.

Patients may present with elevated liver enzymes, jaundice, fatigue, or abdominal pain as symptoms of liver injury. It is essential to regularly monitor liver function tests, especially in the initial stages of therapy, to detect any signs of liver compromise early. Understanding this risk allows healthcare providers to make timely decisions regarding the management of the medication and ensures patient safety effectively.

While peripheral neuropathy, rash, and hyperglycemia are all important considerations in the overall management of a patient on antiretroviral therapy, they do not specifically highlight the immediate need for vigilant monitoring for hepatotoxicity as a primary concern associated with nevirapine.